Assessing cardiovascular risk factors after coronary artery bypass surgery: value of an aggressive strategy including systematic follow-up.

[1]  V. Salomaa,et al.  Long-term prognosis after coronary artery bypass surgery. , 2008, International journal of cardiology.

[2]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[3]  Á. Avezum,et al.  Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. , 2007, American heart journal.

[4]  Ž. Reiner,et al.  Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study) , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[5]  J. Rouleau,et al.  Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease. , 2006, American heart journal.

[6]  M. Simoons,et al.  The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. , 2005, European heart journal.

[7]  Lawrence A Leiter,et al.  Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE. , 2005, European heart journal.

[8]  D. Bouchard,et al.  Biologie vasculaire des greffons coronaires : Un état des lieux , 2004 .

[9]  J. Ornato,et al.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). , 2004, Journal of the American College of Cardiology.

[10]  J. Werba,et al.  Statins in coronary bypass surgery: rationale and clinical use. , 2003, The Annals of thoracic surgery.

[11]  G. De Backer,et al.  Blood pressure is insufficiently controlled in European patients with established coronary heart disease , 2003, Journal of hypertension.

[12]  B. Buxton.  Complete arterial grafting for coronary artery disease? , 2003, The Journal of thoracic and cardiovascular surgery.

[13]  J. McMurray,et al.  Economics of chronic heart failure , 2001, European journal of heart failure.

[14]  D. Wood,et al.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.

[15]  H. Crijns,et al.  Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. , 2001, The American journal of cardiology.

[16]  J. Christenson.  Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization. , 2001, Cardiovascular surgery.

[17]  J. Deckers,et al.  Registration and management of smoking behaviour in patients with coronary heart disease. The EUROASPIRE survey. , 1999, European heart journal.

[18]  J. Brazier,et al.  The SF36 as an outcome measure of services for end stage renal failure. , 1998, Quality in health care : QHC.

[19]  V. Fuster,et al.  Antithrombotic therapy and venous graft disease. , 1998, Current opinion in cardiology.

[20]  D. Wood.  European Action on Secondary Prevention by Intervention to Reduce Events , 1998 .

[21]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[22]  G. Angelini,et al.  The biology of saphenous vein graft occlusion: etiology and strategies for prevention , 1994, Current opinion in cardiology.

[23]  T. Lüscher.  Vascular biology of coronary bypass grafts. , 1991 .

[24]  M. Yacoub,et al.  Vascular reactivity and endothelial function of bypass grafts , 1990, Current opinion in cardiology.

[25]  M. Carrier,et al.  [Vascular biology of coronary bypass grafts. Literature review]. , 2004, Archives des maladies du coeur et des vaisseaux.

[26]  F. Delahaye,et al.  [Epidemiology and economic impact of heart failure in France]. , 1998, Archives des maladies du coeur et des vaisseaux.

[27]  G. D. Gevigney,et al.  Épidémiologie et impact économique de l'insuffisance cardiaque en France , 1998 .

[28]  Philippe Amouyel,et al.  A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .

[29]  EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. , 1997, European heart journal.

[30]  Angelini Gd,et al.  Vascular biology of coronary artery bypass conduits: new solutions to old problems? , 1996 .

[31]  G. Angelini,et al.  Vascular biology of coronary artery bypass conduits: new solutions to old problems? , 1996, Advances in cardiac surgery.